Analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to report ($0.29) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Iovance Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.32). Iovance Biotherapeutics posted earnings of ($0.28) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 3.6%. The company is scheduled to issue its next quarterly earnings results on Monday, May 7th.
On average, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($1.25) per share for the current financial year, with EPS estimates ranging from ($1.40) to ($0.91). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.32) per share, with EPS estimates ranging from ($1.50) to ($0.89). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Iovance Biotherapeutics.
Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.04).
A number of brokerages have commented on IOVA. B. Riley increased their price target on shares of Iovance Biotherapeutics from $18.50 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, March 13th. Zacks Investment Research upgraded shares of Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a research report on Wednesday, January 3rd. Oppenheimer increased their price target on shares of Iovance Biotherapeutics from $13.00 to $19.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. HC Wainwright set a $22.00 price target on shares of Iovance Biotherapeutics and gave the company a “buy” rating in a research report on Thursday, February 8th. Finally, BidaskClub upgraded shares of Iovance Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 27th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.72.
Shares of NASDAQ IOVA opened at $13.85 on Friday. Iovance Biotherapeutics has a one year low of $4.45 and a one year high of $19.90.
Several large investors have recently added to or reduced their stakes in IOVA. Bank of New York Mellon Corp boosted its stake in shares of Iovance Biotherapeutics by 7.1% during the third quarter. Bank of New York Mellon Corp now owns 261,692 shares of the biotechnology company’s stock valued at $2,028,000 after purchasing an additional 17,338 shares during the period. SG Americas Securities LLC boosted its stake in shares of Iovance Biotherapeutics by 385.3% during the third quarter. SG Americas Securities LLC now owns 50,295 shares of the biotechnology company’s stock valued at $390,000 after purchasing an additional 39,931 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Iovance Biotherapeutics during the third quarter valued at approximately $133,000. JPMorgan Chase & Co. boosted its stake in shares of Iovance Biotherapeutics by 63.4% during the third quarter. JPMorgan Chase & Co. now owns 1,779,700 shares of the biotechnology company’s stock valued at $14,059,000 after purchasing an additional 690,527 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of Iovance Biotherapeutics by 44.2% during the third quarter. Wells Fargo & Company MN now owns 103,528 shares of the biotechnology company’s stock valued at $801,000 after purchasing an additional 31,724 shares during the period. 64.44% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/09/0-29-eps-expected-for-iovance-biotherapeutics-inc-iova-this-quarter.html.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.